Product Overview
[Drug Name]
Trade Name: Yatong
English Name: Sulfasalazine Suppositories
Chinese Pinyin: Liudanhuangbiding Shuan
[Ingredients]
The main ingredient of this product is sulfasalazine.
[Properties]
This product is a yellow suppository made from a fatty matrix.
[Indications]
For inflammatory bowel diseases such as ulcerative colitis and nonspecific chronic colitis.
[Dosage and Administration]
Rectal administration. Severe patients should take one tablet each morning, noon, and evening after a bowel movement. Moderate or mild patients should take one tablet each morning and evening after a bowel movement. After significant improvement in symptoms, switch to a maintenance dose of one tablet each night or every other night, preferably before bedtime.
[Adverse Reactions]
Not yet known.
[Contraindications]
Contraindicated in patients allergic to sulfonamides.
[Precautions]
1. Contraindicated in patients allergic to sulfonamides.
2. During placement, a white frost may sometimes form on the surface of the plug due to the matrix. This is a normal phenomenon and does not affect the efficacy.
[Use in Special Populations]
Precautions for Children:
Since sulfonamides can compete with bilirubin for binding sites on plasma proteins, and the acetyltransferase system in newborns is not fully developed, the free blood concentration of sulfonamides increases, increasing the risk of kernicterus. Therefore, these drugs should not be used in newborns and children under 2 years of age.
Precautions for Pregnancy and Breastfeeding:
1. Sulfonamides can cross the placental barrier and reach the fetus. Animal studies have shown teratogenic effects. However, insufficient data are available from human studies. Therefore, their use should not be used by pregnant women. 2. Sulfonamides are secreted in breast milk, with concentrations reaching approximately 50% to 100% of the maternal blood concentration. These drugs may affect infants. Sulfonamides may cause hemolytic anemia in newborns with glucose-6-phosphate dehydrogenase deficiency. Therefore, their use should not be used by breastfeeding women.
Elderly Precautions:
Elderly patients are more likely to experience serious adverse reactions when using sulfonamides. Severe rash, bone marrow suppression, and thrombocytopenia are common serious adverse reactions in the elderly. Therefore, elderly patients should avoid using sulfonamides. When indicated, the decision should be made after weighing the pros and cons.
[Drug Interactions]
1. Concomitant use with urinary alkalinizing agents can increase the solubility of sulfonamides in alkaline urine, leading to increased excretion. 2. Para-aminobenzoic acid can replace sulfonamides in bacterial uptake, antagonizing the antibacterial effects of sulfonamides. Therefore, the two drugs should not be used together. 3. When the following drugs are used together with sulfonamides, the latter can displace the protein binding sites of these drugs or inhibit their metabolism, resulting in prolonged drug action or toxicity. Therefore, the dosage of these drugs should be adjusted when used together with sulfonamides or after sulfonamides. These drugs include oral anticoagulants, oral hypoglycemic agents, methotrexate, phenytoin sodium, and thiopental sodium. 4. Myelosuppressive drugs, when used together with sulfonamides, may enhance the adverse effects of these drugs on the hematopoietic system. If there is an indication for combined use of two classes of drugs, close observation for possible toxic reactions is advised. 5. Long-term combined use of contraceptives (estrogens) with sulfonamides may reduce contraceptive reliability and increase the chance of extramenstrual bleeding. 6. Combining thrombolytics with sulfonamides may increase their potential toxic effects. 7. Combining hepatotoxic drugs with sulfonamides may increase the incidence of hepatotoxicity. Liver function should be monitored in such patients, especially those taking these drugs for extended periods and those with a history of liver disease. 8. Combining photosensitizing drugs with sulfonamides may result in additive photosensitivity. 9. Patients receiving sulfonamide therapy have an increased requirement for vitamin K. 10. Hexamine decomposes in acidic urine to produce formaldehyde, which can form an insoluble precipitate with sulfonamides. This increases the risk of crystalluria, so the two drugs should not be used together. 11. Sulfonamides can displace the plasma protein binding sites of phenylbutazone, enhancing its effects when used together. 12. Concomitant use of sulfinpyrazone with sulfonamides can reduce renal tubular secretion of sulfonamides, leading to elevated and prolonged blood concentrations and potentially toxic effects. Therefore, the sulfonamide dosage may need to be adjusted during or after sulfinpyrazone treatment. During prolonged sulfinpyrazone treatment, monitoring sulfonamide blood concentrations is recommended to facilitate dosage adjustments and ensure safe use. 13. Concomitant use with digitalis or folic acid can reduce absorption and blood concentrations, thus ensuring the effects and efficacy of digitalis. 14. Concomitant use with probenecid can reduce renal tubular sulfonamide excretion, leading to elevated blood concentrations and prolonged effects, potentially leading to toxicity. 15. Concomitant use with neomycin can inhibit intestinal flora, affecting the intestinal breakdown of this drug and reducing its effectiveness.
[Pharmacological Actions]
Anti-inflammatory drug. Pharmacological studies of sulfasalazine suppositories in a rat model of immune ulcerative colitis compared the efficacy of anal suppositories and oral tablets administered orally. The results showed that the anal suppository was significantly more effective than the oral administration. (Absorption, Distribution, and Elimination) Sulfasalazine suppositories enter the intestines and are broken down by intestinal bacteria into sulfapyridine and 5-aminosalicylic acid, which is ultimately excreted in the feces. Sulfapyridine can be absorbed into the bloodstream and ultimately excreted in the urine. In addition to the unchanged sulfapyridine and sulfapyridine, its acetylated form and glucuronic acid conjugates can be found in the bloodstream. Sulfapyridine and its acetylated form can be excreted in the urine.
[Storage]
Store in a dark, airtight container.
[Specifications]
0.5g
[Packaging]
PVC and PE composite film, 6 tablets per box
[Expiration Date]
36 months
[Approval Number]
National Medical Products Approval No. H20056668
[Manufacturer]
Jiangsu Yuanheng Pharmaceutical Co., Ltd.
